Evidence

Beyond the 10-Minute Limit: 4 Actionable Lifestyle Medicine Interventions for Primary Care

NICE backs a saliva test for endometriosis in revised draft guidance. What does the evidence show?

97.3% sensitivity, 94.1% specificity, and NICE still calls its accuracy in primary care unclear. Here is why both things are true.

Could your repeat PPI list become a Barrett’s screening list?

Three practices searched their records for patients on long-term PPIs and invited them for a capsule sponge test. Nearly 9 in 10 eligible, interested patients took it. About 1 in 25 had Barrett’s oesophagus.

Clinical trials in general practice: answering the safety question

Dr Fatima Tahir explains the safeguards that underpin clinical trials in general practice, from ethical review and informed consent to Good Clinical Practice and ongoing safety monitoring.

GLP-1 receptor agonists and obstructive sleep apnoea: what this study means for primary care

A large US matched cohort found lower recorded cerebrovascular, hospital-use and mortality outcomes among people with OSA exposed to GLP-1 receptor agonists. The finding is promising, but observational and not a replacement for standard OSA care.

LatAm-FINGERS: Can lifestyle intervention help prevent dementia?

Does chronic GLP-1 receptor agonist exposure remodel the pancreas? What the evidence actually shows

Preclinical studies show sustained molecular responses to GLP-1 receptor stimulation in pancreatic cell models. What does that mean for primary care, and what does it not show?

Bariatric surgery versus GLP-1RAs: which delivers better CV outcomes in obesity?

NG28 was the biggest NICE change in a decade. Here is what else moved this year.

The February 2026 NG28 update rewrote type 2 diabetes care for UK GPs. What changed, why it matters, and the four other NICE updates from the past year worth knowing.

The Change We Forgot to Finish Talking About

This is a chance for women to get their mojo back.

How to Get Started in Research as a Primary Care Professional in the UK

What your heart failure register is not telling you

Coding, registers and the four pillars in UK primary care

Falling blood pressure and BMI in T2D may signal early dementia

Semaglutide for secondary cardiovascular prevention: An update that may have gone unnoticed – what NICE TA1152 means for primary care

NICE TA1152 establishes semaglutide 2.4 mg as a secondary cardiovascular-prevention treatment for adults with established cardiovascular disease and a BMI of at least 27 kg/m². Niraj Lakhani considers what this means for primary care.

The no-biopsy pathway has arrived, and it stops at the surgery door

FIVE questions to ask before you switch to ambient AI

MASH: where the field is heading, and where primary care starts

New MASH licences clarify the fibrosis stages they cover, while the staging pathway remains the practical question for primary care.

State of Child Health 2026

Chronic Kidney Disease in Primary Care: Small Changes That Make a Big Difference

CKD is common, but progression is not inevitable.

Biggest weight loss, biggest trade-off?

A BMJ network meta-analysis of 262 trials and 99,791 participants compares 19 obesity drugs. The ranking matters less than what sits behind each position.

BMI and type 2 diabetes: how much do ethnicity, age, and sex matter?

Unseen in primary care: how patients with complex mental health difficulties experience accessing help

Around a quarter of patients presenting to primary care with mental health difficulties meet criteria for personality disorder, yet only 1 to 1.5% have a coded diagnosis. A new qualitative study explores what that gap looks like from the patient side.

Primary Care Research: From an Optional Extra to an Essential Part of Modern General Practice

Almost 90% of NHS patient contacts happen in primary care, yet most research still happens somewhere else. Dr Fatima Tahir on why that gap matters, and what practices stand to gain from closing it.

Finerenone may slow kidney decline in glomerular disease

A prespecified exploratory analysis of the FIND-CKD trial reports slower eGFR decline with finerenone in chronic kidney disease due to glomerular diseases.